Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta.

Abstract

Acute myeloid leukemia (AML) with deranged core-binding factor beta (CBFβ) is usually associated with a favorable prognosis with 50-70% of patients cured using contemporary treatments. We analyzed the prognostic significance of clinical features on 58 patients with CBFβ-AML aged ≤60 years. Increasing age was the only predictor for survival (P <0.001), with an optimal cut-point at 43 years. White blood cells (WBCs) at diagnosis emerged as an independent risk factor for relapse incidence (P = 0.017), with 1.1% increase of hazard for each 1.0 × 10(9) /L WBC increment. KIT mutations lacked prognostic value for survival and showed only a trend for relapse incidence (P = 0.069).

• Authors: Roberto Cairoli, Alessandro Beghini, Mauro Turrini, Giambattista Bertani, Gianpaolo Nadali, Francesco Rodeghiero, Carlo Castagnola, Francesca Lazzaroni, Michele Nichelatti, Felicetto Ferrara, Giovanni Pizzolo, Enrico Pogliani, Giuseppe Rossi, Giovanni Martinelli, Enrica Morra
• Journal: American journal of hematology (Am J Hematol) Vol. 88 Issue 7 Pg. 594-600 (Jul 2013) ISSN: 1096-8652 [Electronic] United States
• PMID: 23619823 (Publication Type: Journal Article)
• Copyright: Copyright © 2013 Wiley Periodicals, Inc.

Chemical References

• Antineoplastic Agents
• CBFB protein, human
• Core Binding Factor beta Subunit
• Proto-Oncogene Proteins c-kit

Topics

• Adolescent
• Adult
• Age Factors
• Antineoplastic Agents (therapeutic use)
• Core Binding Factor beta Subunit (blood, genetics)
• Female
• Follow-Up Studies
• Gene Expression
• Hematopoietic Stem Cell Transplantation
• Humans
• Leukemia, Myeloid, Acute (diagnosis, genetics, mortality, therapy)
• Leukocyte Count
• Leukocytes (pathology)
• Male
• Middle Aged
• Mutation
• Prognosis
• Proto-Oncogene Proteins c-kit (blood, genetics)
• Sex Factors
• Survival Analysis